Kura Oncology’s Ziftomenib Gains FDA Priority Review, Promising Commercial Success in AML Treatment

Analyst Joseph Pantginis from H.C. Wainwright reiterated a Buy rating on Kura Oncology (KURA – Research Report) and keeping the price target at $40.00.

Joseph Pantginis has given his Buy rating due to a combination of factors surrounding Kura Oncology’s recent progress and potential in the treatment of acute myeloid leukemia (AML). The FDA’s acceptance of the New Drug Application (NDA) for ziftomenib, a treatment for relapsed or refractory AML with an NPM1 mutation, under Priority Review is a significant milestone. This acceptance underscores the strength of the clinical data from the Phase 2 KOMET-001 trial, which met its primary endpoint and demonstrated a favorable benefit-risk profile.
Furthermore, ziftomenib’s potential to become the first FDA-approved menin inhibitor for this specific subset of AML patients highlights its importance. The trial results showed a complete remission rate with full or partial hematologic recovery in a notable percentage of patients, alongside a favorable safety profile. These factors, combined with the upcoming presentation of the full data at ASCO, position Kura Oncology well for future commercial success, justifying the Buy rating.

Pantginis covers the Healthcare sector, focusing on stocks such as Cytokinetics, Actinium Pharmaceuticals, and Viking Therapeutics. According to TipRanks, Pantginis has an average return of -20.8% and a 26.26% success rate on recommended stocks.

In another report released on May 23, Wedbush also maintained a Buy rating on the stock with a $36.00 price target.